Merck's fundamental strength is reinforced by Keytruda combo data showing significant renal cancer improvements, supporting continued revenue growth despite minor price dips. Technicals remain constructive with strong oncology platform expansion likely to outweigh temporary market noise.

Market sentiment stays bullish as Merck's Keytruda combos strengthen the oncology platform and Wall Street maintains bullish views. The stock dip while market gains is likely short-term noise amid positive clinical developments.

Long-term outlook remains strong with renal cancer combo data showing significant improvement in primary endpoints, though patent questions for Keytruda warrant monitoring. The core pipeline and financial guidance support continued growth despite some competitive pressure from peers like BMY.

Technical signals remain positive with Keytruda combo data supporting fundamental strength and the stock holding near recent highs of $123.77. Data-driven analysis shows consistent bullish momentum despite minor daily fluctuations.